- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, March 7, 2025
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Articles from The Kansas City Star and Shreveport Times referenced a news item published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). AJMC’s article, “Trump Endorses Budget That Would Slash Medicaid Funding,” reported on President Donald Trump’s budget endorsement and what it would mean for Medicaid should the budget be adopted.
An article published on AJMC.com, titled “5 Specialty Care Shortages in Rural Communities,” was referenced in an article from The Cottage Grove Sentinel. It covered 5 areas of specialty care that are lacking in rural communities and make it harder for patients in those communities to receive needed care.
An article from Clinical Leader referenced the Biosimilar Approvals database published by AJMC’s sister site, The Center for Biosimilars®. The database lists all biosimilar medications that have been approved for use in the US and the European Union, their therapeutic uses, and the originator and its manufacturer.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
